Endocrine Abstracts

Background: TE is indicated for the treatment of carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors.Objective: To evaluate the effects of a proton pump inhibitor (OMP) and H2 antagonist (FAM) on the PK of TE and its active metabolite LP-778902 via an open-label study of OMP (40 mg orally QD × 4 days) or FAM (40 mg orally BID × 4 days) with a single 250 mg oral dose of TE. Eligible subjects: healthy, nonsmoking, aged &...